Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Orthocell Ltd ( (AU:OCC) ) has provided an announcement.
Orthocell reported record quarterly revenue of $3.2 million for the December 2025 quarter, its seventh consecutive quarter of record sales, driven by strong Remplir nerve repair product uptake in existing markets and initial U.S. sales. The company’s hybrid U.S. market entry strategy—combining specialist distributors with internal field leadership—is gaining traction, with distributor coverage now spanning more than 25 states, 23 hospital Value Analysis Committee approvals, and multiple medical education events completed, while Canadian market entry is underway. Supported by $49.4 million in cash reserves, no debt and an expected R&D tax refund, Orthocell is well positioned to accelerate Remplir adoption and pursue a step-change in revenue as it scales across North America.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a Perth-based regenerative medicine company listed on the ASX that develops and commercialises advanced biological products for nerve repair, including its flagship Remplir™ device. The company focuses on expanding its presence in key markets such as Australia, Singapore, the United States and Canada, targeting the growing global nerve repair market, including the sizeable US$1.6 billion U.S. segment.
Average Trading Volume: 709,132
Technical Sentiment Signal: Buy
Current Market Cap: A$303.9M
For an in-depth examination of OCC stock, go to TipRanks’ Overview page.